BAMF Health and Corewell Health Haworth Innovative Therapeutics Clinic plan to collaborate on a clinical trial to test targeted radiation therapy for cancer patients.
The phase I trial is sponsored by Y-mAbs Therapeutics and will include both adolescent and adult patients with recurrent or resistant small-cell lung cancer, sarcoma, and malignant melanoma. Trial participants will receive tumor-targeting treatment with an antibody that binds to a protein called GD-2 on the surface of the cancer cells, then a radioisotope infusion that binds to the antibody and delivers the radiation to cancer cells, BAMF Health said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
